DOCSLIB.ORG

Accessory NUMM (NDUFS6) Subunit Harbors a Zn-Binding Site and Is Essential for Biogenesis of Mitochondrial Complex I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Accessory NUMM (NDUFS6) Subunit Harbors a Zn-Binding Site and Is Essential for Biogenesis of Mitochondrial Complex I Accessory NUMM (NDUFS6) subunit harbors a Zn-binding site and is essential for biogenesis of mitochondrial complex I Katarzyna Kmitaa, Christophe Wirthb, Judith Warnauc, Sergio Guerrero-Castillod,e, Carola Hunteb, Gerhard Hummerc, Ville R. I. Kailaf, Klaus Zwickerg, Ulrich Brandtd,e, and Volker Zickermanna,e,1 aStructural Bioenergetics Group, Institute of Biochemistry II, Medical School, Goethe University, 60438 Frankfurt am Main, Germany; bInstitute for Biochemistry and Molecular Biology, ZBMZ, BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg Germany; cDepartment of Theoretical Biophysics, Max Planck Institute of Biophysics, 60438 Frankfurt am Main, Germany; dNijmegen Center for Mitochondrial Disorders, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; eCluster of Excellence Frankfurt “Macromolecular Complexes”, Goethe University, 60438 Frankfurt am Main, Germany; fDepartment Chemie, Technische Universität München, 85747 Garching, Germany; and gInstitute of Biochemistry I, Medical School, Goethe University, 60590 Frankfurt am Main, Germany Edited by Hartmut Michel, Max Planck Institute of Biophysics, Frankfurt, Germany, and approved March 11, 2015 (received for review December 19, 2014) Mitochondrial proton-pumping NADH:ubiquinone oxidoreductase harbors a conserved putative Zn-binding motif, comprising three (respiratory complex I) comprises more than 40 polypeptides and cysteines and one histidine in its C-terminal part (11). Zn binding contains eight canonical FeS clusters. The integration of subunits to complex I was previously reported for bovine complex I but its and insertion of cofactors into the nascent complex is a com- functional relevance and the position of the Zn site remained elu- plicated multistep process that is aided by assembly factors. We sive (12, 13). A poly-alanine model of the orthologous 13-kDa show that the accessory NUMM subunit of complex I (human subunit was tentatively fitted into the electron microscopic NDUFS6) harbors a Zn-binding site and resolve its position by structure of bovine complex I but Zn binding was not shown (5). X-ray crystallography. Chromosomal deletion of the NUMM gene In human, mutations leading to the loss of the orthologous or mutation of Zn-binding residues blocked a late step of complex I NDUFS6 subunit or exchange of one of the three conserved assembly. An accumulating assembly intermediate lacked acces- cysteine residues were shown to cause fatal diseases (14, 15). A BIOCHEMISTRY sory subunit N7BM (NDUFA12), whereas a paralog of this subunit, mouse model to study complex I-linked diseases was generated the assembly factor N7BML (NDUFAF2), was found firmly bound by knock down of the corresponding gene (16). instead. EPR spectroscopic analysis and metal content determina- We analyzed the functional significance of the Zn-binding site tion after chromatographic purification of the assembly interme- of the NUMM subunit in Y. lipolytica complex I and determined diate showed that NUMM is required for insertion or stabilization its position in the X-ray structure of the enzyme complex by Zn of FeS cluster N4. anomalous scattering. We found that deletion of the NUMM gene or site-directed mutagenesis of Zn ligands compromised a assembly | metal protein | FeS cluster | NDUFAF2 | NDUFA12 late step of complex I biogenesis that is required for stable in- sertion of FeS cluster N4. roton-pumping NADH:ubiquinone oxidoreductase (respira- Ptory complex I) is a multisubunit membrane protein complex Results with a central function in aerobic energy metabolism (1, 2). Deletion of the NUMM Subunit Impairs Complex I Biogenesis. To Fourteen central subunits that harbor the bioenergetic core investigate the function of the NUMM subunit and its proposed functions are conserved from bacteria to humans. In addition, Zn-binding site (11) (Fig. S1A) in respiratory complex I we eukaryotic complex I comprises around 30 accessory subunits of largely unknown function. The structures of bacterial and mito- Significance chondrial complex I were analyzed by X-ray crystallography and electron microscopy (3–6). The central subunits can be assigned Respiratory complex I is the largest membrane protein complex to functional modules for NADH oxidation (N-module), ubi- in mitochondria and has a central function in energy metabo- quinone reduction (Q-module), and proton pumping (P-module). lism. Numerous human diseases are linked with complex I The subunits forming the N- and Q- module harbor a chain of dysfunction or assembly defects. The concerted assembly of FeS clusters that connects the NADH oxidation site with the more than 40 subunits and the insertion of cofactors is aided by ubiquinone reduction site where the redox energy is released to specific chaperones. In addition to eight FeS clusters, complex I drive proton translocation. comprises a Zn-binding site of unknown function. Combining The assembly of complex I subunits is a multistep process that X-ray structural analysis of complex I crystals with quantum proceeds via defined intermediates and is aided by a number of chemical modeling and proteomic and spectroscopic analysis assembly factors (7). It also requires the concerted insertion of a purified assembly intermediate, we show that accessory of preformed FeS clusters into several subunits of the N- and subunit NUMM (human ortholog NDUFS6) binds Zn at the in- Q-module (8). Dysfunction of complex I is the most frequent terface of two functional modules of the enzyme complex and cause of mitochondrial disorders (9). Pathogenic mutations were is required for a specific step of complex I biogenesis. identified not only in central subunits, encoded by either nuclear or mitochondrial DNA, but also in accessory subunits and as- Author contributions: K.K. and V.Z. designed research; K.K., C.W., J.W., S.G.-C., C.H., G.H., V.R.I.K., K.Z., U.B., and V.Z. performed research; K.K., C.W., J.W., S.G.-C., C.H., G.H., sembly factors. The aerobic yeast Yarrowia lipolytica has been V.R.I.K., K.Z., U.B., and V.Z. analyzed data; and K.K., C.W., J.W., S.G.-C., C.H., G.H., V.R.I.K., established as a yeast genetic model system to study structure K.Z., U.B., and V.Z. wrote the paper. and function of eukaryotic complex I, as well as complex I linked The authors declare no conflict of interest. diseases (10). This article is a PNAS Direct Submission. In this study, we focused on the accessory subunit NUMM of 1To whom correspondence should be addressed. Email: [email protected]. Y. lipolytica complex I. NUMM belongs to a limited subset of This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. accessory subunits that is already found in α-proteobacteria and 1073/pnas.1424353112/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1424353112 PNAS Early Edition | 1of6 Downloaded by guest on October 1, 2021 Table 1. Complex I content and ubiquinone reductase activities detect by mass spectrometry because they are highly hydrophobic in mitochondrial membranes and lack suitable cleavage sites (18). Complex I was mainly found † Strain Complex I content*, % Complex I activity ,% in monomeric form but also assembled into higher molecular mass supercomplexes (20); membrane arm subcomplexes, very nummΔ 41 44 likely representing assembly intermediates, were detected at n7bmlΔ 30 83 lower molecular mass (Fig. S2). n7bmΔ 26 35 In strain nummΔ we detected assembly of nearly all expected C97ANUMM 54 63 subunits (Fig. S2). However, we also found a higher fraction of H110ANUMM 60 76 unassembled subunits and subcomplexes of the peripheral arm. C125ANUMM 55 63 Notably, accessory subunit N7BM did not assemble into complex C128ANUMM 54 37 I and was almost exclusively found in free form at the migration *Complex I content was assessed as nonphysiological NADH:hexaamminer- front in the Blue-Native gel (Fig. 1 and Fig. S2). On the other uthenium (III) oxidoreductase activity and compared with parental strain hand, an additional protein was found to be associated with the − − GB20 for chromosomal deletions (100% = 1.41 μmol∙min 1∙mg 1) and with nearly complete complex I subassembly in nummΔ.The27.6-kDa plasmid complemented nummΔ deletion strain for NUMM point mutants protein, mainly detected in free form in the parental strain, was (100% = 1.14 μmol∙min−1∙mg−1). identified as YALI0D27082p in the Y. lipolytica genome (21) and †Inhibitor sensitive dNADH:decylubiquinone oxidoreductase activity was − − has sequence homology to a known complex I assembly factor normalized to complex I content (100% = 0.55 μmol∙min 1 CI 1 for GB20 Homo sapiens Bos taurus −1 −1 called NDUFAF2 in ,B17.2Lin ,and13.4L to compare with chromosomal deletions and 100% = 0.46 μmol∙min CI Neurospora crassa B Δ in (Fig. S1 ) (22, 23). Because its N-terminal for plasmid complemented numm deletion to compare with NUMM Y. lipolytica point mutants). half was also clearly homologous to complex I sub- unit N7BM (Fig. S1D), we named the protein N7BML for N7BM like. Indeed, N7BM is also homologous to subunits NDUFA12, generated a chromosomal deletion of the entire reading frame B17.2, and nuo13.4 from H. sapiens, B. taurus,andN. crassa,re- of the corresponding NUMM gene by homologous recombina- spectively (Fig. S1D) that are paralogs of the respective assembly tion. Complex I content of mitochondrial membranes from the factors indicated above (22–24). deletion strain was decreased to 41% as assessed by NADH: hexammineruthenium (HAR) oxidoreductase activity and nor- A Functional Link Between NUMM, N7BM, and N7BML in Complex I malized dNADH:decylubiquinone (DBQ) oxidoreductase activity Assembly. To investigate the role of N7BML in the complex I dropped to 44% of the parental strain (Table 1). Complementa- assembly process and its functional relation to its paralog, complex tion with variants carrying mutations in the putative Zn ligating I subunit N7BM, we deleted the corresponding genes from the residues C97, H110, C125, C128 did not restore complex I content Y.
Load more

Recommended publications
  • High-Throughput, Pooled Sequencing Identifies Mutations in NUBPL And
    ARTICLES High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency Sarah E Calvo1–3,10, Elena J Tucker4,5,10, Alison G Compton4,10, Denise M Kirby4, Gabriel Crawford3, Noel P Burtt3, Manuel Rivas1,3, Candace Guiducci3, Damien L Bruno4, Olga A Goldberger1,2, Michelle C Redman3, Esko Wiltshire6,7, Callum J Wilson8, David Altshuler1,3,9, Stacey B Gabriel3, Mark J Daly1,3, David R Thorburn4,5 & Vamsi K Mootha1–3 Discovering the molecular basis of mitochondrial respiratory chain disease is challenging given the large number of both mitochondrial and nuclear genes that are involved. We report a strategy of focused candidate gene prediction, high-throughput sequencing and experimental validation to uncover the molecular basis of mitochondrial complex I disorders. We created seven pools of DNA from a cohort of 103 cases and 42 healthy controls and then performed deep sequencing of 103 candidate genes to identify 151 rare variants that were predicted to affect protein function. We established genetic diagnoses in 13 of 60 previously unsolved cases using confirmatory experiments, including cDNA complementation to show that mutations in NUBPL and FOXRED1 can cause complex I deficiency. Our study illustrates how large-scale sequencing, coupled with functional prediction and experimental validation, can be used to identify causal mutations in individual cases. Complex I of the mitochondrial respiratory chain is a large ~1-MDa ­assembly factors are probably required, as suggested by the 20 factors macromolecular machine composed of 45 protein subunits encoded necessary for assembly of the smaller complex IV9 and by cohort by both the nuclear and mitochondrial (mtDNA) genomes.
    [Show full text]
  • Neurodevelopmental Signatures of Narcotic and Neuropsychiatric Risk Factors in 3D Human-Derived Forebrain Organoids
    Molecular Psychiatry www.nature.com/mp ARTICLE OPEN Neurodevelopmental signatures of narcotic and neuropsychiatric risk factors in 3D human-derived forebrain organoids 1 1 1 1 2 2 3 Michael Notaras , Aiman Lodhi , Estibaliz✉ Barrio-Alonso , Careen Foord , Tori Rodrick , Drew Jones , Haoyun Fang , David Greening 3,4 and Dilek Colak 1,5 © The Author(s) 2021 It is widely accepted that narcotic use during pregnancy and specific environmental factors (e.g., maternal immune activation and chronic stress) may increase risk of neuropsychiatric illness in offspring. However, little progress has been made in defining human- specific in utero neurodevelopmental pathology due to ethical and technical challenges associated with accessing human prenatal brain tissue. Here we utilized human induced pluripotent stem cells (hiPSCs) to generate reproducible organoids that recapitulate dorsal forebrain development including early corticogenesis. We systemically exposed organoid samples to chemically defined “enviromimetic” compounds to examine the developmental effects of various narcotic and neuropsychiatric-related risk factors within tissue of human origin. In tandem experiments conducted in parallel, we modeled exposure to opiates (μ-opioid agonist endomorphin), cannabinoids (WIN 55,212-2), alcohol (ethanol), smoking (nicotine), chronic stress (human cortisol), and maternal immune activation (human Interleukin-17a; IL17a). Human-derived dorsal forebrain organoids were consequently analyzed via an array of unbiased and high-throughput analytical approaches, including state-of-the-art TMT-16plex liquid chromatography/mass- spectrometry (LC/MS) proteomics, hybrid MS metabolomics, and flow cytometry panels to determine cell-cycle dynamics and rates of cell death. This pipeline subsequently revealed both common and unique proteome, reactome, and metabolome alterations as a consequence of enviromimetic modeling of narcotic use and neuropsychiatric-related risk factors in tissue of human origin.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: achusetts 021 15 (US). THE BROAD INSTITUTE, A61K 51/10 (2006.01) G01N 33/574 (2006.01) INC. [US/US]; 415 Main Street, Cambridge, Massachu C07K 14/705 (2006.01) A61K 47/68 (2017.01) setts 02142 (US). MASSACHUSETTS INSTITUTE OF G01N 33/53 (2006.01) TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US2017/055625 (72) Inventors; and (71) Applicants: KUCHROO, Vijay K. [IN/US]; 30 Fairhaven (22) International Filing Date: Road, Newton, Massachusetts 02149 (US). ANDERSON, 06 October 2017 (06.10.2017) Ana Carrizosa [US/US]; 110 Cypress Street, Brookline, (25) Filing Language: English Massachusetts 02445 (US). MADI, Asaf [US/US]; c/o The Brigham and Women's Hospital, Inc., 75 Francis (26) Publication Language: English Street, Boston, Massachusetts 021 15 (US). CHIHARA, (30) Priority Data: Norio [US/US]; c/o The Brigham and Women's Hospital, 62/405,835 07 October 2016 (07.10.2016) US Inc., 75 Francis Street, Boston, Massachusetts 021 15 (US). REGEV, Aviv [US/US]; 15a Ellsworth Ave, Cambridge, (71) Applicants: THE BRIGHAM AND WOMEN'S HOSPI¬ Massachusetts 02139 (US). SINGER, Meromit [US/US]; TAL, INC. [US/US]; 75 Francis Street, Boston, Mass c/o The Broad Institute, Inc., 415 Main Street, Cambridge, (54) Title: MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS CD4 FIG.
    [Show full text]
  • Genome-Wide Contribution of Common Short-Tandem Repeats to Parkinson’S Disease Genetic Risk
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.01.21259645; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Genome-wide contribution of common Short-Tandem Repeats to Parkinson’s Disease genetic risk Bernabe I. Bustos1*, Kimberley Billingsley2*, Cornelis Blauwendraat2, J. Raphael Gibbs3, Ziv Gan-Or4,5,6, Dimitri Krainc1, Andrew B. Singleton2† and Steven J. Lubbe1†. For the International Parkinson’s Disease Genomics Consortium (IPDGC). 1) Ken and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA. 2) Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA 3) Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. 4) The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada 5) Department of Human Genetics, McGill University, Montréal, QC, Canada 6) Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada *These authors contributed equally to this work 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.07.01.21259645; this version posted July 5, 2021.
    [Show full text]
  • Purinergic Receptor Transactivation by the Β2-Adrenergic Receptor Increases Intracellular Ca2+ in Non-Excitable Cells
    Molecular Pharmacology Fast Forward. Published on March 9, 2017 as DOI: 10.1124/mol.116.106419 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2016/106419 Title page: Purinergic receptor transactivation by the β2-adrenergic receptor increases intracellular Ca2+ in non-excitable cells. Wayne Stallaert, Emma T van der Westhuizen, Anne-Marie Schönegge, Bianca Plouffe, Mireille Downloaded from Hogue, Viktoria Lukashova, Asuka Inoue, Satoru Ishida, Junken Aoki, Christian Le Gouill & Michel Bouvier. molpharm.aspetjournals.org Department of Biochemistry, Université de Montréal, Montréal, QC, Canada (WS, ETvdW, A- MS, BP, MB). Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada (WS, ETvdW, A-MS, BP, MH, VL, CLG, MB). Monash Institute for at ASPET Journals on September 30, 2021 Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (ETvdW). Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (AI, SI, JA). Japan Science and Technology Agency (JST), Precursory Research for Embryonic Science and Technology (PRESTO), Kawaguchi, Saitama, Japan (AI). Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology (AMED-CREST), Chiyoda-ku, Tokyo, Japan (JA). 1 Molecular Pharmacology Fast Forward. Published on March 9, 2017 as DOI: 10.1124/mol.116.106419 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2016/106419 Running title page: a) Running title: β2AR transactivation of purinergic receptors b) Corresponding author: Michel Bouvier, IRIC - Université de Montréal, P.O. Box 6128 Succursale Centre-Ville, Montréal, Qc. Canada, H3C 3J7. Tel: +1-514-343-6319.
    [Show full text]
  • Genetic Associations with Rapid Motor and Cognitive Deterioration in Parkinson’S Disease
    Genetic Associations With Rapid Motor and Cognitive Deterioration in Parkinson’s Disease Ling-Xiao Cao Beijing Tiantan Hospital Yingshan Piao Beijing Tiantan Hospital Yue Huang ( [email protected] ) Beijing Tiantan Hospital https://orcid.org/0000-0001-6051-2241 Research Keywords: Parkinson's disease, susceptibility genes, single nucleotide polymorphisms, motor progression, rapid cognitive decline Posted Date: March 1st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-245594/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/18 Abstract Background: Parkinson’s disease (PD) is caused by the interplay of genetic and environmental factors during brain aging. About 90 single nucleotide polymorphisms (SNPs) have been recently discovered associating with PD, but their associations with PD clinical features have not been fully characterized yet. Methods: Clinical data of 377 patients with PD who enrolled in Parkinson's Progression Markers Initiative (PPMI) study were obtained. Patients with rapid cognitive or motor progression were determined through clinical assessments over ve years follow-up. In addition, genetic information of 50 targeted SNPs was extracted from the genetic database of NeuroX for the same cohort. Genetic associations with rapid motor and cognitive dysfunction of PD were analyzed using SPSS-logistic regression. Results: Among 377 patients with PD, there are more male (31%) than female (17%) prone to have rapid motor progression (p<0.01), who demonstrate 16 points increase in the motor part assessment of MDS- UPDRS. There is no gender difference in rapid cognitive deterioration. Four SNPs (rs11724635, rs12528068, rs591323, rs17649553) were associated with fast cognitive decline (p<0.05) and the extended 50 SNPs researches excellent predicative value of area under curve (AUC) at 0.961.
    [Show full text]
  • Leigh Syndrome
    Leigh syndrome What is Leigh syndrome? Leigh syndrome is an inherited progressive neurodegenerative disease characterized by developmental delays or regression, low muscle tone, neuropathy, and severe episodes of illness that can lead to early death.1,2 Individuals with Leigh syndrome have defects in one of many proteins involved in the mitochondrial respiratory chain complexes that produce energy in cells.1 These protein defects cause lesions in tissues that require large amounts of energy, including the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord.1 Clinical symptoms depend on which areas of the central nervous system are involved.1,2 Leigh syndrome is also known as subacute necrotizing encephalomyelopathy.3 What are the symptoms of Leigh syndrome and what treatment is available? Leigh syndrome is a disease that varies in age at onset and rate of progression. Signs of Leigh syndrome can be seen before birth, but are usually noticed soon after birth. Signs and symptoms may include: 2,3,4 • Hypotonia (low muscle tone) • Intellectual and physical developmental delay and regression • Digestive problems and failure to thrive • Cerebellar ataxia (difficulty coordinating movements) • Peripheral neuropathy (disease affecting nerves) • Hypertrophic cardiomyopathy • Breathing problems, leading to respiratory failure • Metabolic or neurological crisis (serious episode of illness) often triggered by an infection During a crisis, symptoms can progress to respiratory problems, seizures, coma, and possibly death. There is no cure for Leigh syndrome. Treatment is supportive. Approximately 50% of affected individuals die by three years of age, although some patients may survive beyond childhood.4 How is Leigh Syndrome inherited? Autosomal recessive Leigh syndrome is caused by mutations in at least 36 different genes,3 including FOXRED1, NDUFAF2, NDUFS4, NDUFS7, NDUFV1, COX15, SURF1 and LRPPRC.
    [Show full text]
  • Overview of Research on Fusion Genes in Prostate Cancer
    2011 Review Article Overview of research on fusion genes in prostate cancer Chunjiao Song1,2, Huan Chen3 1Medical Research Center, Shaoxing People’s Hospital, Shaoxing University School of Medicine, Shaoxing 312000, China; 2Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China; 3Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou 310000, China Contributions: (I) Conception and design: C Song; (II) Administrative support: Shaoxing Municipal Health and Family Planning Science and Technology Innovation Project (2017CX004) and Shaoxing Public Welfare Applied Research Project (2018C30058); (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Song; (V) Data analysis and interpretation: H Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chunjiao Song. No. 568 Zhongxing Bei Road, Shaoxing 312000, China. Email: [email protected]. Abstract: Fusion genes are known to drive and promote carcinogenesis and cancer progression. In recent years, the rapid development of biotechnologies has led to the discovery of a large number of fusion genes in prostate cancer specimens. To further investigate them, we summarized the fusion genes. We searched related articles in PubMed, CNKI (Chinese National Knowledge Infrastructure) and other databases, and the data of 92 literatures were summarized after preliminary screening. In this review, we summarized approximated 400 fusion genes since the first specific fusion TMPRSS2-ERG was discovered in prostate cancer in 2005. Some of these are prostate cancer specific, some are high-frequency in the prostate cancer of a certain ethnic group. This is a summary of scientific research in related fields and suggests that some fusion genes may become biomarkers or the targets for individualized therapies.
    [Show full text]
  • Inheritest 500 PLUS
    Inheritest® 500 PLUS 525 genes Specimen ID: 00000000010 Container ID: H0651 Control ID: Acct #: LCA-BN Phone: SAMPLE REPORT, F-630049 Patient Details Specimen Details Physician Details DOB: 01/01/1991 Date Collected: 08/05/2019 12:00 (Local) Ordering: Age (yyy/mm/dd): 028/07/04 Date Received: 08/06/2019 Referring: Gender: Female Date Entered: 08/06/2019 ID: Patient ID: 00000000010 Date Reported: 08/21/2019 15:29 (Local) NPI: Ethnicity: Unknown Specimen Type: Blood Lab ID: MNEGA Indication: Carrier screening Genetic Counselor: None SUMMARY: POSITIVE POSITIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Spinal muscular atrophy AT RISK AT RISK to be a silent carrier (2+0). For ethnic-specific risk (SMN1) 2 copies of SMN1; positive for revisions see Methods/Limitations. Genetic counseling is NMID: NM_000344 c.*3+80T>G SNP recommended. Risk: AT INCREASED RISK FOR AFFECTED PREGNANCY. See Additional Clinical Information. NEGATIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Cystic fibrosis NEGATIVE This result reduces, but does not eliminate the risk to be a (CFTR) carrier. NMID: NM_000492 Risk: NOT at an increased risk for an affected pregnancy. Fragile X syndrome NEGATIVE: Not a carrier of a fragile X expansion. (FMR1) 29 and 36 repeats NMID: NM_002024 Risk: NOT at an increased risk for an affected pregnancy. ALL OTHER DISORDERS NEGATIVE This result reduces, but does not eliminate the risk to be a carrier. Risk: The individual is NOT at an increased risk for having a pregnancy that is affected with one of the disorders covered by this test. For partner's gene-specific risks, visit www.integratedgenetics.com.
    [Show full text]
  • Electron Transport Chain Activity Is a Predictor and Target for Venetoclax Sensitivity in Multiple Myeloma
    ARTICLE https://doi.org/10.1038/s41467-020-15051-z OPEN Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma Richa Bajpai1,7, Aditi Sharma 1,7, Abhinav Achreja2,3, Claudia L. Edgar1, Changyong Wei1, Arusha A. Siddiqa1, Vikas A. Gupta1, Shannon M. Matulis1, Samuel K. McBrayer 4, Anjali Mittal3,5, Manali Rupji 6, Benjamin G. Barwick 1, Sagar Lonial1, Ajay K. Nooka 1, Lawrence H. Boise 1, Deepak Nagrath2,3,5 & ✉ Mala Shanmugam 1 1234567890():,; The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has reduced mitochondrial respiration. Consistent with this, low electron transport chain (ETC) Complex I and Complex II activities correlate with venetoclax sensitivity. Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clinical trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax. We demonstrate that ETC inhibition increases BCL-2 dependence and the ‘primed’ state via the ATF4-BIM/NOXA axis. Further, SQR activity correlates with venetoclax sensitivity in patient samples irrespective of t(11;14) status. Use of SQR activity in a functional-biomarker informed manner may better select for MM patients responsive to venetoclax therapy. 1 Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA.
    [Show full text]